Announced
Completed
Syncona led a £20m series A funding round in Kesmalea.
Financials
Transaction Value£20m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-
Sources
Tags
United Kingdom
Minority
Friendly
Completed
Acquisition
drug discovery
Single Bidder
small molecule therapeutics
Domestic
Pharmaceuticals
Private Equity
Private
Synopsis
Syncona, a British closed-ended investment trust, led a £20m series A funding round in Kesmalea, a small molecule drug discovery company.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
No credit card required
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.